Chromadex Corp (NASDAQ:CDXC) Collaborates With NIH-NIAID to Support the Study of Its Patent-Protected NR Ingredient

The virus that causes COVID-19 can live for several hours and up to three days either in the air or on surfaces. This is according to research findings from Rocky Mountain Laboratories in Hamilton. At a different turn of events, Chromadex Corp (NASDAQ:CDXC) and the National Institute of Allergy and Infectious Diseases (NIAID) will carry out a study to assess the potential of Niagen.

The joint efforts will focus on whether or not the administration of Niagen can decrease virus-related burden, particularly in mouse and hamster models of COVID-19. The study will be an extension of the ChromaDex External Research Program (CERP), whereby the company offers researchers its NR ingredient and placebos at no cost.

Building on the current trans-NIAID efforts of understanding the transmission of SARS–CoV-2

Transmission of SARS-CoV-2 can occur in different ways, according to the World Health Organization (WHO). Direct, indirect, or close contact with infected people are just a few of the transmission methods. There is also mother-to-child and animal-to-human transmission. The infection primarily causes respiratory illness, which begins by being mild, gets to a severe status, and could eventually lead to death.

There has been a lot of urgency for the need to mitigate the spread of the virus to reduce mortality. According to the CEO of ChromaDex, Rob Fried, the company is enthusiastic about helping find answers in response to COVID-19 infection.

Fried says, ‘’… this research is a logical next step to assess whether increasing NAD+ levels with NR supplementation benefits the innate immune response in a preclinical COVID-19 model to reduce viral burden…’’

Researchers Compare Environment Effects Of SARS-Cov-2 and SARS-Cov-1

There have been a lot of discussions among researchers about SARS-CoV-1. The virus emerged from China in 2002, circulated very quickly across the globe, and by 2003 it had infected hundreds of people. However, measures such as case isolation and intensive contact tracing were extensively exercised to eradicate the virus.

In the stability study, researchers are concluding that SARS-CoV-2 is similar to SARS-Cov-1. However, the former seems to have hit largely, and according to scientists, the people spreading it may not be knowing that they are infected. This means the spread measure applied in SARS-Cov-1 may not be applicable for SARS-CoV-2.